[Use of inhibitors of the angiotensin-converting enzyme and the beta-adrenoblocker metoprolol combined in treatment of chronic cardiac insufficiency]. / Lechenie khronicheskoi serdechnoi nedostatochnosti ingibitorom angiotenzinprevrashchaiushchego fermenta v sochetanii s beta-blokatorom metoprololom.

Clinical-and-hemodynamic effects were studied of a supplementary use of a selective beta-adrenoblocker metoprolol in an ongoing therapy of chronic cardiac insufficiency (CCI) with inhibitors of the angiotensin-converting enzyme (ACEI) and diuretics. It has been found out that long (over 8 weeks) course of therapy supplemented with metoprolol results in improvement of the left ventricular systolic function and lowering of the functional class. Long-term administration of metoprolol enhances tolerance to a graded physical exercise in CCI patients, which observation is accompanied by a more economic character of its performance. The findings secured validate the expediency of a supplementary use of the beta-adrenoblocker metoprolol in the routine regimen of the supporting treatment of CCI patients involving the use of ACEI plus a diuretic.

[The clinico-hemodynamic effects of losartan in treating patients with chronic heart failure]. / Kliniko-gemodinamicheskie éffekty lozartana pri lechenii bol'nykh s khronicheskoi serdechnoi nedostatochnost'iu.

Clinical and hemodynamic effects were studied of the blockader of AII receptors lozartan in patients with chronic cardiac insufficiency (ChCI). Inclusion of losartan into the conventional therapy of ChCI is accompanied by a lowering of the functional class in patients and improvement of haemodynamic maintenance of the physical exercise performance as evidenced by veloergometry. An 8-week's course of lozartan therapy leads also to a decrease in the anterior-posterior dimensions of the left auricle and an increase in the left ventricular ejection fraction in ChCI patients.